FTZ 61: Viatris Moves to Expand Drug Production in Puerto Rico

FTZ News: The U.S. Foreign-Trade Zones Board published an official notice on Tuesday, August 11, 2026, showing that Viatris Pharmaceuticals LLC plans to expand medication production at its facility in Vega Baja, Puerto Rico, inside Foreign-Trade Zone 61. The notice appears in the Federal Register at 91 FR 51658 and marks the initial step in the approval process for using special customs benefits.

Viatris, a major American pharmaceutical company with a long track record in both generic and branded drugs, operates a facility at Road 689, Kilometer 1.9 in Vega Baja. The site previously operated under names linked to Pfizer and is now part of Viatris’s global manufacturing network. The new request would allow the company to bring in foreign raw materials without immediately paying customs duties, process and package them inside the zone, and then either export the finished products or pay the duties when shipping them into the U.S. market.

Why This Matters

Puerto Rico has served for decades as one of the main hubs for pharmaceutical manufacturing on American soil. Foreign-Trade Zone 61, active since 1980, lets drugmakers lower operating costs and stay competitive against overseas producers. At a time when the United States still relies heavily on drug imports from India, China, and Europe, every step that strengthens domestic production—even in a territory like Puerto Rico—carries strategic weight.

The request comes as America’s medicine supply chain continues to show vulnerabilities. Past shortages of critical drugs and recent tariff pressures have pushed companies to lean more on tools like foreign-trade zones. With this move, Viatris is signaling that it intends to keep part of its production on U.S. soil and take advantage of existing legal tools to control costs.

Implications for Jobs and Puerto Rico’s Economy

While the Federal Register notice does not spell out exact production volumes or new job numbers, experience shows that manufacturing activity inside Puerto Rico’s FTZs usually helps preserve and create mid- to high-skill jobs. The pharmaceutical industry remains one of the few sectors that still generates meaningful value-added activity on the island, and this notice could send a positive signal that major American companies plan to stay.

Critics may call it just another routine administrative step that does not automatically mean new investment or large-scale hiring. Supporters of foreign-trade zones counter that without these tools, many companies would simply move production offshore. In the current climate, where U.S. trade policy emphasizes strengthening domestic manufacturing, these requests show companies continuing to use available legal mechanisms to stay competitive.

In the end, Viatris’s notice is a practical, clear-eyed move by an American company seeking to keep drug production inside the United States under existing rules. Whether the request ultimately leads to final approval and real production growth will depend on further review by the FTZ Board and market conditions. But the core point is straightforward: American companies are still looking for ways to keep manufacturing at home—and foreign-trade zones remain one of their primary tools./.